PUBLICATION

Embryonic and larval zebrafish models for the discovery of new bioactive compounds against TB

Authors
Antunes, S.S., Forn-Cuní, G., Romeiro, N.C., Spaink, H.P., Verbeek, F.J., Muzitano, M.F.
ID
ZDB-PUB-240909-8
Date
2024
Source
Drug discovery today   29(11): 104163 (Review)
Registered Authors
Spaink, Herman P., Verbeek, Fons J.
Keywords
Mycobacterium marinum, drug discovery, tuberculosis, zebrafish
MeSH Terms
  • Mycobacterium marinum/drug effects
  • Antitubercular Agents*/pharmacology
  • Tuberculosis*/drug therapy
  • Tuberculosis*/microbiology
  • Drug Discovery*/methods
  • Animals
  • Disease Models, Animal*
  • Zebrafish*/embryology
  • Zebrafish*/microbiology
  • Larva*/drug effects
  • Larva*/microbiology
(all 11)
PubMed
39245344 Full text @ Drug Discov. Today
Abstract
TB is a world health challenge the treatment of which is impacted by the rise of drug-resistant strains. Thus, there is an urgent need for new antitubercular compounds and novel approaches to improve current TB therapy. The zebrafish animal model has become increasingly relevant as an experimental system. It has proven particularly useful during early development for aiding TB drug discovery, supporting both the discovery of new insights into mycobacterial pathogenesis and the evaluation of therapeutical toxicity and efficacy in vivo. In this review, we summarize the past two decades of zebrafish-Mycobacterium marinum research and discuss its contribution to the field of bioactive antituberculosis therapy development.
Genes / Markers
Figures
No images available
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping